Antibody Products for Cancer Research
Padza proudly offers a comprehensive portfolio of locally designed and produced antibodies, developed by a team of skilled scientists and professionals. As one of Iran’s leading knowledge-based companies, we are committed to advancing cancer research and diagnostics through innovative antibody technologies.
Our antibody products are classified into the following categories, tailored for diverse research needs:
- Unconjugated Monoclonal Antibodies (43 Types): Pure, high-specific monoclonal antibodies designed for precise targeting in cancer studies and diagnostics.
- Unconjugated Polyclonal Antibodies (7 Types): Versatile, pure polyclonal antibodies, ideal for applications such as biomarker detection and immune response analysis in cancer research.
- Fluorscent Conjugated Antibodies (17 Types): Fluorescently labeled antibodies (6 monoclonal, 11 polyclonal), optimized for applications requiring fluorescent markers, such as flow cytometry.
- Enzyme Conjugated Antibodies (9 Types): Enzyme-labeled antibodies (2 monoclonal, 7 polyclonal) designed for use in enzyme-linked assays like ELISA and other visualization techniques.
- Apoptosis Kit: Specialized kits for apoptosis detection, essential for understanding cancer cell death mechanisms and evaluating therapeutic effectiveness.
Padza Antibody Products
Padza’s antibodies are meticulously designed to deliver universal compatibility across various applications and laboratory techniques, including:
- Flow Cytometry
- ELISA
- Western Blot
- Immunohistochemistry
- Immunocytochemistry
Thanks to their intelligent and innovative design, Padza’s antibodies exhibit exceptional specificity and adaptability, effectively identifying their target epitopes across multiple species, including humans, mice, rats, rabbits, monkeys, sheep, goats, dogs, and cats.
- Monoclonal Antibodies: Produced in Balb/c mice for high specificity and precision.
- Polyclonal Antibodies: Generated using New Zealand rabbits and Saanen goats for versatility and broad applicability.